ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	1.49T
Revenue (ttm)	278.64B
Net Income (ttm)	32.39B
Shares Out	20.15M
EPS (ttm)	1,689.86
PE Ratio	43.85
Forward PE	32.16
Dividend	500.00 (0.67%)
Ex-Dividend Date	Dec 27, 2024

Volume	65,267
Average Volume	103,485
Open	76,500
Previous Close	76,200
Day's Range	73,600 - 76,800
52-Week Range	72,000 - 120,800
Beta	0.58
RSI	36.86
Earnings Date	Apr 28, 2025

About ST Pharm

ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co....

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2023, ST Pharm's revenue was 284.99 billion, an increase of 14.31% compared to the previous year's 249.32 billion. Earnings were 19.58 billion, an increase of 8.78%.